

14 October 2021

Company Announcements Office  
Australian Securities Exchange  
20 Bridge Street  
**Sydney NSW 2000**

**Notice under Section 708A(5)(e) of the *Corporations Act 2001 (Cth)***

On 14 October 2021, Regeneus Ltd (the "**Company**") issued 2,898,551 fully paid ordinary shares in accordance with the terms of its Subscription Agreement with New Life Sciences Capital, LLC, which was announced to the market on 7<sup>th</sup> May 2021.

Accordingly the Company gives notice under section 708A(5)(e) of the *Corporations Act 2001 (Cth)* (the "**Corporations Act**") that:

1. the abovementioned ordinary shares were issued without disclosure to investors under Part 6D.2 of the *Corporations Act*;
2. as at the date of this notice the Company has complied with:
  - (a) the provisions of Chapter 2M of the *Corporations Act* as they apply to the Company; and
  - (b) section 674 of the *Corporations Act*; and
3. as at the date of this notice there is no "excluded information" (as defined in subsection 708A(7) of the *Corporations Act*) which is required to be disclosed by the Company.

On behalf of the Board of Regeneus Ltd



Helen Leung  
Company Secretary  
**Regeneus Ltd**